Navigation Links
Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One
Date:5/5/2010

BIO CONVENTION, CHICAGO, Illinois, May 5, 2010 /PRNewswire/ -- Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI(R) in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.

It has now been discovered that TB does not lie "dormant" but is actually waging a constant war with the host, constantly re-infecting the lungs. Provided that the host is healthy, it has the upper hand and usually keeps the TB in check - LTBI. TB is particularly tricky to eliminate as it can be either replicating, when it can be killed by the antibiotics, or non-replicating when antibiotics are useless. The long, nine month course of antibiotics is needed to ensure that all traces of the non-replicating form are eliminated from the lungs. Further details can be found at http://www.archivelfarma.com/hipotesi_an.html

Archivel's novel, two pronged approach combines a one month course of antibiotic to eliminate the bacteria in the replicating stage and two injections of the company's RUTI vaccine that stimulates the body's own immune system to fight the TB bacteria. This combination approach reduces the treatment time from nine months to one, is easier to manage, less expensive, more effective and more likely to be done completely. The company estimates that cost comparison between the current and new treatment, when allowing for all the logistical costs means that the new treatment costs around half that of the old treatment.

Further information at http://www.archivelfarma.com/noticies_an.html

Full details can be found in the accompanying press release AF004002 entitled "Archivel's RUTI, a novel therapeutic vaccine to Latent Tuberculosis, starts phase II clinical trials in South Africa" and press release AF004001 entitled "Major breakthrough in fight to eliminate Tuberculosis".

Further information on Archivel at http://www.archivelfarma.com

Archivel Farma S.L., 61 c/ Fogars de Tordera, Poligon Industrial Bonavista, 08916 BADALONA, Spain. Tel +34-93-497-2456, +34-637-057432, ORue@archivelfarma.com

Press information and illustrations

Nigel Robson, Vortex PR, Tel +44(0)1481-233080, nigel@vortexpr.com

RUTI is a registered trademark of Archivel Farma S.L.


'/>"/>
SOURCE Archivel Farma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a ... therapies for metabolic and endocrine disorders, today announced that ... will deliver a corporate presentation at H.C. Wainwright & ... held April 3, 2017 at the St. Regis Hotel ... presentation are as follows: H.C. ...
(Date:3/28/2017)... , March 28, 2017 Biostage, Inc. ... company developing bioengineered organ implants to treat cancers and ... today announced that Jim McGorry, CEO of ... BioEngineering panel at the MassBio 2017 Annual ... PM ET in Cambrige, Massachussetts. The 3D Printing ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... and diminished effectiveness over time. A recent study published in STEM CELLS suggests ... stimulating subventricular zone (SVZ) stem cells to produce more neural cells. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... weigh modules. These weigh modules are designed according to European Hygienic Engineering ... , As fully integrated weighing solutions, SWB805 MultiMount weigh modules reduce contamination ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
Breaking Biology News(10 mins):